Group 1 - The core point of the article is that China National Pharmaceutical Group (国药控股) has released a performance report for China National Pharmaceutical Group Co., Ltd. (国药一致) for the year 2025, indicating a mixed financial performance with a slight decline in revenue but a significant increase in net profit [1] Group 2 - The total operating revenue for the year 2025 is reported at 73.416 billion yuan, reflecting a year-on-year decrease of 1.29% [1] - The net profit attributable to shareholders of the listed company is 1.136 billion yuan, which shows a substantial year-on-year increase of 76.8% [1] - The basic earnings per share (EPS) is reported at 2.04 yuan [1]

Group 1 - The core point of the article is that China National Pharmaceutical Group (国药控股) has released its performance report for China National Pharmaceutical Group Co., Ltd. (国药一致) for the year 2025, showing a total operating revenue of 73.416 billion yuan, a year-on-year decrease of 1.29% [1] - The net profit attributable to shareholders of the listed company is 1.136 billion yuan, which represents a significant year-on-year increase of 76.8% [1] - The basic earnings per share (EPS) is reported at 2.04 yuan [1]

Core Viewpoint - China National Pharmaceutical Group (国药控股) announced the preliminary performance report for China National Pharmaceutical Group Co., Ltd. (国药一致) for the fiscal year 2025, highlighting a mixed financial performance with a decline in revenue but significant growth in profits [1] Financial Performance Summary - The total operating revenue for China National Pharmaceutical Group Co., Ltd. reached 73.416 billion yuan, representing a year-on-year decrease of 1.29% [1] - Operating profit amounted to 1.513 billion yuan, showing a substantial year-on-year increase of 163.80% [1] - Total profit was reported at 1.509 billion yuan, which is a year-on-year growth of 162.22% [1] - The net profit attributable to shareholders was 1.136 billion yuan, reflecting a year-on-year increase of 76.80% [1] - Basic earnings per share increased by 77.39% year-on-year [1] - The weighted average return on net assets rose by 2.59 percentage points compared to the previous year [1] Factors Influencing Profit Growth - The profit growth was primarily driven by a reduction in asset impairment provisions for goodwill and intangible assets, which decreased by 686 million yuan year-on-year [1] - Additionally, adjustments in store operations led to a decline in fixed costs such as labor and rent [1]

Core Viewpoint - China National Pharmaceutical Group (国药控股) announced the preliminary performance report for China National Pharmaceutical Group Co., Ltd. (国药一致) for the fiscal year 2025, highlighting a mixed performance with a slight decline in revenue but significant growth in profits [1] Financial Performance Summary - The total operating revenue for China National Pharmaceutical Group Co., Ltd. reached 73.416 billion RMB, representing a year-on-year decrease of 1.29% [1] - Operating profit amounted to 1.513 billion RMB, showing a substantial year-on-year increase of 163.80% [1] - Total profit for the period was 1.509 billion RMB, which is a year-on-year growth of 162.22% [1] - Net profit attributable to shareholders was 1.136 billion RMB, reflecting a year-on-year increase of 76.80% [1] - Basic earnings per share increased by 77.39% year-on-year [1] - The weighted average return on equity rose by 2.59 percentage points compared to the previous year [1] Factors Contributing to Profit Growth - The profit growth was primarily driven by a reduction in asset impairment provisions for goodwill and intangible assets, which decreased by 686 million RMB year-on-year [1] - Additionally, adjustments in store operations led to a decrease in fixed costs such as labor and rent [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容而產生或因倚賴該等內 容而引致之任何損失承擔任何責任。 海外監管公告 國藥集團一致藥業股份有限公司 2025 年度業績快報 本公告乃根據香港聯合交易所有限公司證券上市規則第 13.10B 條作出。 茲載列國藥控股股份有限公司旗下一間 A 股及 B 股於深圳證券交易所上市的附屬公司，國藥 集團一致藥業股份有限公司，在深圳證券交易所網站刊登的《國藥集團一致藥業股份有限公 司 2025 年度業績快報》，僅供參閱。 承董事會命 國藥控股股份有限公司 董事長 晉斌 中國，上海 2026 年 3 月 17 日 於本公告日期，執行董事為連萬勇先生及楊秉華先生；非執行董事為晉斌先生、陳啟宇先生、祖敬 先生、邢永剛先生、馬躍先生、陳玉卿先生、文德鏞先生及李瑩女士；獨立非執行董事為李培育先 生、吳德龍先生、俞衛鋒先生、石晟昊先生及陳威如先生。 证券代码：000028、200028 证券简称：国药一致、一致 B 公告编号：2026-04 国药集团一致药业股份有限公司 2025年度 ...

Group 1: Acquisition Announcements - Company Shapais plans to acquire 100% equity of Shanghai Qinli for 528 million yuan, which will indirectly give it 100% ownership of Shanghai Tianlun Hospital [1] - Company Kute Intelligent intends to sign a memorandum of understanding to acquire controlling interest in a major operating company of South Korea's apM Group for approximately 500 million yuan [2] Group 2: Financial Performance - Company Fuyao Glass reported a net profit of 9.312 billion yuan for 2025, representing a year-on-year increase of 24.20%, with total revenue of 45.787 billion yuan, up 16.65% [3] - Company Wancheng Group announced a net profit of 1.345 billion yuan for 2025, a significant increase of 358.09%, with total revenue of 51.459 billion yuan, up 59.17% [4] - Company Sinopharm Unity reported a net profit of 1.136 billion yuan for 2025, reflecting a year-on-year growth of 76.80%, despite total revenue declining by 1.29% to 73.416 billion yuan [5] Group 3: Shareholding Changes - Company Haotaitai announced that shareholder Hou Pengde plans to reduce his holdings by no more than 12.072 million shares, accounting for up to 3% of the total share capital [6] - Company Jinyinhai reported that shareholder Haihui Wealth intends to reduce its holdings by no more than 7.5 million shares, representing 4.31% of the total shares, due to personal funding needs [7] - Company Zhaoyan New Drug announced that shareholders Gu Xiaolei and Gu Meifang adjusted their combined reduction plan to no more than 3% of the total share capital, changing the method to a combination of centralized bidding and block trading [8] Group 4: Operational Issues - Company Huitian New Materials reported a fire incident at its wholly-owned subsidiary, leading to a temporary production halt until the cause is determined, with potential impacts on the company's 2026 performance [11] - Company Huide Technology announced that its wholly-owned subsidiary needs to pay back taxes of 9.6798 million yuan and late fees of 2.6215 million yuan, which will affect the company's 2025 net profit by approximately 12.3013 million yuan [12]

证券代码：000028、200028 证券简称：国药一致、一致 B 公告编号：2026-07 国药集团一致药业股份有限公司 关于公司高级管理人员变更的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 国药集团一致药业股份有限公司（以下简称"公司"、"国药一致"）董事 会于近日收到公司副总经理王矗先生的书面辞任报告。因工作调动原因，王矗先 生申请辞去公司副总经理职务，辞任后不在公司担任其他任何职务，辞任报告自 送达公司董事会之日起生效，王矗先生的辞任不会影响公司的正常经营。 截至本公告披露日，王矗先生未持有公司股票。公司董事会对王矗先生在任 职期间的勤勉尽责工作表示衷心感谢。 截至本公告披露日，池国光先生未持有公司股份，与其他持有本公司 5%以 上股份的股东、公司其他董事、高级管理人员之间不存在关联关系。池国光先生 未曾受过中国证监会及其他有关部门的处罚和证券交易所纪律处分，未涉嫌犯罪 被司法机关立案侦查或涉嫌违法违规被中国证监会立案稽查，尚未有明确结论； 黄敏春女士、池国光先生和王虎彪先生均符合《公司法》等相关法律法规、 规范性文件、《深圳证券交易所股票上 ...

证券代码：000028、200028 证券简称：国药一致、一致 B 公告编号：2026-06 国药集团一致药业股份有限公司 关于计提资产减值准备的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 国药集团一致药业股份有限公司（以下简称"公司"）于 2026 年 3 月 16 日召开第十届董事会风险内控与审计委员会 2026 年第一次会议和第十届董事会 2026 年第三次临时会议，审议通过了《关于拟计提资产减值准备的议案》，根 据《深圳证券交易所股票上市规则》等相关规定，现将公司计提资产减值准备的 具体情况公告如下： 根据《企业会计准则》、《深圳证券交易所股票上市规则》以及公司会计政 策等相关规定，为了更加客观真实反映公司截至 2025 年 12 月 31 日的财务状况 和资产价值，基于谨慎性原则，公司 2025 年度相关资产计提的资产减值准备情 况如下： 一、本次计提资产减值准备情况概述 根据《企业会计准则》及公司会计政策相关规定，基于谨慎性原则，公司对 合并报表范围内各类资产进行了检查和分析，对可能发生资产减值损失的相关资 产计提减值准备。具体情况如下表 ...

证券代码：000028、200028 证券简称：国药一致、一致 B 公告编号：2026-05 国药集团一致药业股份有限公司 第十届董事会 2026 年第三次临时会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 表决结果：9 票同意，0 票反对，0 票弃权。 董事会同意公司根据《企业会计准则》及公司会计政策的相关规定，2025 年度共 计提各项资产减值准备合计 37,882.46 万元。董事会认为：公司本次资产减值准备计提 符合《企业会计准则》和公司相关会计政策的规定，本次计提资产减值准备基于谨慎性 原则，依据充分，能够真实地反映公司的财务状况及经营成果。 本议案经第十届董事会风险内控与审计委员会 2026 年第一次会议审议通过。 具体内容详见公司在巨潮资讯网披露的相关公告。 2. 审议了《关于聘任公司副总经理的议案》 表决结果：9 票同意，0 票反对，0 票弃权。 董事会同意聘任黄敏春女士、池国光先生、王虎彪先生任国药一致副总经理。上述 候选人任职资格已经董事会提名委员会事前审查通过。 一、董事会会议召开情况 国药集团一致药业股份有限公司（以下简称 ...

Financial Performance - Total revenue for 2025 was CNY 73.42 billion, a decrease of 1.29% year-on-year[6] - Operating profit reached CNY 1.51 billion, an increase of 163.80% compared to the previous year[6] - Net profit attributable to shareholders was CNY 1.14 billion, up 76.80% year-on-year[6] - Basic earnings per share increased by 77.39% to CNY 2.04[6] - The weighted average return on equity rose by 2.59 percentage points to 6.26%[6] Segment Performance - The distribution segment generated CNY 53.32 billion in revenue, a year-on-year increase of 0.64%[6] - The retail segment (Guoda Pharmacy) reported revenue of CNY 20.98 billion, a decline of 6.16% year-on-year[7] - Guoda Pharmacy's net profit improved to a loss of CNY 0.22 billion, but showed a year-on-year increase of 80.36%[7] Strategic Focus - The company aims to focus on high-quality development and strategic adjustments in 2026[7] Asset Position - The total assets at the end of the reporting period were CNY 49.10 billion, an increase of 3.24% from the beginning of the period[4]